Ranitidine's cancer signal largely reflected reporting bias, not carcinogenicity

Design

Disproportionality analysis of FAERS and JADER with active comparator, plus systematic review

Population

Spontaneous adverse event reports for ranitidine and famotidine; comparative cohort studies

Primary outcome

Cancer reporting signals with bias-mitigation methods

Effect

140,985 FAERS cancer reports 2020–21; JADER PRR 3.54 fell to 0.92; most cohorts showed no excess risk

Ranitidine was withdrawn worldwide in 2020 after NDMA, a probable human carcinogen, was found in products. This Drug Safety study analysed the US FAERS and Japanese JADER spontaneous reporting databases with four signal-detection methods, compared ranitidine with famotidine, split the data before and after the recall, and added a systematic review of comparative cohort studies.

FAERS logged 140,985 ranitidine cancer reports in 2020–21, more than two thirds of all cancer reports in that period, most from consumers and clustered where regulatory action and litigation were active. Crude analyses produced strong signals for gastrointestinal and genitourinary cancers, but they weakened sharply or disappeared against famotidine and in the pre-recall period. In JADER, a reporting ratio of 3.54 fell to 0.92 when all reports were included. Most large cohort studies showed no increase in overall or site-specific cancer.

The immediate clinical point: a patient worried about past ranitidine use can be told the best evidence does not show increased cancer risk, and no screening is needed on that basis. The wider point for prescribers and pharmacovigilance teams is methodological: a spontaneous-report signal after publicity or litigation needs an active comparator and a time restriction before it is believed.

• Reassure patients worried about past ranitidine use that large cohort studies mostly showed no increased cancer risk.
• Do not arrange cancer screening solely because of previous ranitidine use.
• Treat spontaneous-report signals that follow publicity or litigation with caution until tested against an active comparator.
• Check pre-alert and post-alert periods separately when interpreting pharmacovigilance data.

Why it matters

It shows how a regulatory alert can manufacture a safety signal that patients and prescribers then act on.

Don't overread it

The analysis addresses the NDMA-driven reporting signal; it does not prove NDMA contamination was harmless.

The statistics, in plain English

A proportional reporting ratio compares how often an event is reported with one drug against all others. A value of 3.54 falling to 0.92 when the comparison is broadened means the apparent excess came from how reports were selected, not from the drug.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.